Single-ascending Dose Study of Kylo-12 in Healthy Subjects
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.